Tg Therapeutics (TGTX) traded up 1.14 % during a 24 hours period ending at 07:54 AM Central Europe on Tuesday 27th. One Tg Therapeutics stock can currently be bought for about USD 54.79 on popular exchanges. Current supply of Tg Therapeutics stocks is 141.7 mn. Tg Therapeutics has a current market capitalization of USD 7.7 bn and approximately USD 65.1 mn worth of Tg Therapeutics was traded on exchanges in the last 24 hours. Since last month end, Tg Therapeutics has traded -2.49 % down. Simple moving average of last 200 days is at USD 43.21. The highest price of past 52 weeks was recorded at USD 59.3 on 07/09/2026. 52 weeks low was at USD 26.76 on 03/12/2026.
Here is how related stocks have performed in the past 24 hours:
Hecla Mining (HL) traded up 0.94 % and now trades at USD 13.98. Current market capitalisation for Hecla Mining is USD 9.2 bn. Hecla Mining has a current price to earnings ratio of 16.98.
Consumers Pwr : Cms Prb (CMS-PB) traded down -0.34 % and now trades at USD 73.75. Current market capitalisation for Consumers Pwr : Cms Prb is USD 9.2 bn.
Leonardo (DRS) traded up 3.85 % and now trades at USD 35.84. Current market capitalisation for Leonardo is USD 9.3 bn. Current price/earnings ratio for Leonardo is 29.06.
Sirius Xm (SIRI) traded down -0.76 % and now trades at USD 27.42. Sirius Xm has a market capitalisation of USD 9.3 bn. Sirius Xm has a current price to earnings ratio of 11.1.
Protagonist Therapeutics (PTGX) traded up 1.37 % and now trades at USD 140.32. Current market capitalisation for Protagonist Therapeutics is USD 9.1 bn. Protagonist Therapeutics has a current price to earnings ratio of 112.68.
About Tg Therapeutics
TG Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New York, United States, specializing in the acquisition, development, and commercialization of innovative pharmaceutical products for the treatment of cancer and other therapeutic needs. The company is actively pursuing two therapies targeted towards hematological malignancies, specifically relapsed and refractory non-Hodgkins lymphoma. You can find more information about their activities and offerings on their official website, www.tgtherapeutics.com , or through trading on the Nasdaq stock exchange.
